This complete resource captures state-of-the-art strategies and the accelerated pace of discovery that is revolutionizing what is known about ischemic stroke and its treatment. Therapeutics for acute management, secondary prevention, recovery, rehabilitation, asymptomatic cerebral ischemia, and implementation of stroke systems of care are all discussed in this comprehensive yet practical guide. Chapters are authored by leading academicians with extensive clinical practice experience from all over the world and feature the scientific evidence behind prevailing therapeutic strategies for managing ischemic cerebrovascular disease. The specialist or general practitioner will gain critical knowledge in stroke management, current clinical challenges and promising new therapies under investigation.

This book illustrates the importance and significance of regenerative medicine in stroke recovery. It discusses stem-cell-based treatment strategies and offers mechanistic insights into their role in neurological recovery. It also examines the challenges and advances in using adult stem cells for enhanced therapeutic efficacy. Further, it presents the strategies as well as the strengths and weaknesses of various delivery methods to administer stem cells in ischemic stroke. It examines the role of non-coding RNA in our understanding the stroke pathogenesis, their regulatory role in ischemic stroke and potential as biomarkers and therapeutic targets. Lastly, it explores exosomes in the treatment of stroke, and the underlying mechanism of their action as therapeutic vectors for stroke. Given its scope, it is an excellent resource for neurologists, neuroscientists and researchers involved in regenerative therapy for stroke.

On the threshold of an exciting new era for acute stroke diagnosis and treatment, the Third International Symposium on Thrombolytic Therapy in Acute Ischemic Stroke was held in Nara, Japan, in April 1994. The symposium brought together some 200 basic and clinical scientists for presentations and discussions of issues vital to the understanding of thrombolytic therapy. This volume compiles the major presentations of the symposium, with attention to applications of new diagnostic measures such as diffusion and perfusion MRI, contrast-enhanced transcranial Doppler and angioscopy. Other presentations examine the mechanisms of ischemia/reperfusion injury, hemorrhagic transformation, and reocclusion, with reviews of recent developments in thrombolytic agents. The proceedings of the symposium will be of special interest to researchers, physicians, and students in the fields of neurology, neurosurgery, and nuclear medicine, as well as those in pharmacology, critical care medicine, and related fields.

There has been an enormous increase in information relating to microRNA (miRNA) and its strategic role in numerous diseases. This book reviews the emerging role of microRNAs in cerebral ischemia, providing comprehensive details of the links between this small RNA molecule and ischemic stroke, the more prevalent of the two main types of stroke. The chapters address questions relating to microRNA’s function in various pathological features of stroke, like oxidative stress, excitotoxicity and cell death, as well as its role as a biomarker and diagnostic agent, and the current therapeutic interventions. Further, the book highlights the latest research on how miRNAs contribute to neuroregeneration following stroke, discussing the myriad computational tools and databases used in miRNA research, and decsribes how how miRNA modulates other cerebrovascular diseases. The book concludes with fresh insights into the effect of long non-coding RNA in cerebral ischemia.

BM would like to declare that he has filed patents for the application of arginine-rich peptide as neuroprotective agents for stroke and other neurological disorders. RRR patents licensed by Neuronasal Inc., a company that he also consults for and has equity interest in. All other Topic Editors declare no competing interests with regards to the Research Topic subject.

A critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in academia and industry, to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases. Currently stroke can be successfully treated through the administration of a thrombolytic, but the therapeutic window is short and many patients are not able to receive treatment. Only about 30% of patients are "cured" by available treatments. In 5 sections, the proposed volume will explore historical and novel neuroprotection mechanisms and targets, new and combination therapies, as well as clinical trial design for some of the recent bench-side research.